modelPovidoneIodine
Extends from Pharmacolibrary.Drugs.ATC.D.D09AA09.
Information
| name: | PovidoneIodine | |
| ATC code: | D09AA09 | route: | topical |
| compartments: | 1 | |
| dosage: | 1 | mg |
| volume of distribution: | 1 | L |
| clearance: | 0 | |
| other parameters in model implementation | ||
Povidone-iodine is a broad-spectrum antiseptic for topical application in the treatment and prevention of wound infection. It is used on skin, in wounds, and on mucous membranes for disinfection. It is widely approved and used today as an over-the-counter antiseptic in surgical scrubs, wound care, and infection control.
Pharmacokinetics
No pharmacokinetic parameters for povidone-iodine as a drug entity are reported in published literature for human subjects; systemic absorption is minimal when used topically. Most PK data available refer to iodine absorption from povidone-iodine, mainly in case reports or animal studies under specific conditions (e.g., burns, mucosal application), not suitable for PK modeling.
References
Lin, YS, et al., & Milgrom, P (2018). Pharmacokinetics of Iodine and Fluoride following Application of an Anticaries Varnish in Adults. JDR clinical and translational research 3(3) 238–245. DOI:10.1177/2380084418771930 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30938600
Below, H, et al., & Rudolph, P (2006). Systemic iodine absorption after preoperative antisepsis using povidone-iodine in cataract surgery-- an open controlled study. Dermatology (Basel, Switzerland) 212 Suppl 1 41–46. DOI:10.1159/000089198 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16490974
Tahirović, H, et al., & Gnat, D (2009). Maternal and neonatal urinary iodine excretion and neonatal TSH in relation to use of antiseptic during caesarean section in an iodine sufficient area. Journal of pediatric endocrinology & metabolism : JPEM 22(12) 1145–1149. DOI:10.1515/jpem.2009.22.12.1145 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20333874
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)